FDA approves three new natural food color additives
THE US Food and Drug Administration said on Friday that it had granted permissions to three new color additives, marking them as safe to use in food products and expanding the range of natural-source colors available to manufacturers.
Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said last month that the agency
plans to remove
synthetic food dyes from the US food supply by revoking the authorizations of some and working with the industry to voluntarily remove others.
'For too long, our food system has relied on synthetic, petroleum-based dyes that offer no nutritional value and pose unnecessary health risks,' Kennedy had said in a statement.
The health regulator approved Galdieria extract blue - a blue color derived from the unicellular red algae Galdieria sulphuraria - for use in non-alcoholic beverages, fruit juices, candy, breakfast cereal coatings, ice cream and frozen dairy desserts, among others. The petition was submitted by the French company Fermentalg.
It also approved butterfly pea flower extract, a blue color that is produced through the water extraction of the plant's dried flower petals. This helps achieve a range of shades that include bright blues, intense purple and natural greens and is already approved for use in fruit and vegetable juices, alcoholic beverages and ready-to-drink tea.
Friday's approval expands its use for coloring ready-to-eat cereal, crackers, snack mixes and some chips.
The FDA also approved calcium phosphate, which imparts a white color, for use in ready-to-eat chicken products, white candy melts, doughnut sugar and sugar for coated candy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
20 hours ago
- New Straits Times
Off-label drug prescriptions a growing challenge in Malaysia
Off-label drug prescriptions — where medications are used outside their approved indications, dosages, age groups or routes of administration — have become a significant issue in Malaysia's healthcare landscape. This practice raises legal, ethical and safety concerns for patients and practitioners. Legal ambiguity continues to surround off-label prescriptions in Malaysia, with loopholes giving practitioners some leeway. However, this flexibility raises ethical questions, particularly regarding patient safety. Simply obtaining patient consent or informing them about the off-label nature of a prescription does not eliminate the risk of adverse drug reactions associated with such use. The core issue is that legal or procedural compliance alone cannot protect patients from harm when clinical evidence is lacking for off-label use. Off-label prescribing occurs when doctors prescribe a drug for a purpose, patient group or method not included in its official approval by regulatory bodies, such as Malaysia's Drug Control Authority (DCA) or the US Food and Drug Administration. For example, Methotrexate, originally approved for cancer, is sometimes prescribed off-label for psoriasis, potentially exposing patients to severe side effects not anticipated for their condition. Studies indicate that off-label prescriptions may account for up to 50 per cent of all medication use, with particularly high rates in paediatric and geriatric populations. In children, this practice is often driven by a lack of suitable paediatric formulations, insufficient clinical trial data and the absence of approved medications for certain conditions. In Malaysia, common off-label prescriptions for children include anti-asthmatic and cough and cold medications. The primary concern with off-label drug use is the risk of adverse drug reactions (ADRs), which can range from mild side effects to life-threatening complications. Notable historical examples include the thalidomide tragedy of the 1950s, where off-label use in pregnant women led to thousands of birth defects. Pharmacists play a critical role in monitoring and reporting suspected ADRs, while doctors are expected to be fully informed about any drug they prescribe off-label, basing their decisions on scientific evidence and clinical judgment. In Malaysia, the Control of Drugs and Cosmetics Regulations 1984 mandates that all pharmaceutical products must be registered with the DCA, including details of intended use, dosage and target patient groups. However, many drugs used in hospitals, especially for children, are either unlicensed for paediatric use or are prescribed off-label due to the exclusion of children from clinical trials during drug development. This regulatory gap places the burden of responsibility on medical practitioners, who must carefully weigh the risks and benefits when considering off-label prescriptions. The lack of clear legal guidance means that the practice is largely left to the discretion of individual doctors, with potential medico-legal implications if adverse outcomes occur. The Patents Act 1983 should also support incremental innovations but with safeguards requiring full disclosure of clinical trial safety data. Experts and researchers emphasise the urgent need for well-designed clinical studies on commonly prescribed off-label medications, especially in vulnerable groups like children and the elderly. Enhanced monitoring, better practitioner education and clearer legal frameworks are essential to ensure patient safety and uphold ethical standards in medical practice. As off-label prescribing continues to be a common, yet controversial, aspect of modern medicine, striking the right balance between innovation, patient safety and regulatory oversight remains a pressing challenge for the healthcare system.
Malaysian Reserve
4 days ago
- Malaysian Reserve
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ — The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. 'This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease,' says Dr. Shavelle, who led the landmark procedure. 'Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life.' This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. 'The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day,' says Dr. Shavelle. 'It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being.' The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as 'Best Hospital' for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit
The Star
5 days ago
- The Star
US FDA launches AI tool to reduce time taken for scientific reviews
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly (Reuters) -The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews. "Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers," said FDA Commissioner Marty Makary. The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets. Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision. Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts. "Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff," the FDA said. In May, the regulator said it would fully integrate AI by June 30, following an experimental run. (Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
